RayKnowChina Research Map
Shortlist

RecruitingBreast cancerN/A

Registered title, quoted from ClinicalTrials.gov

Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Xijing Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorXijing Hospital空军军医大学西京医院Xi'anHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06938360, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 70 years; sex: women only

    Registered eligibility fields

  2. Nipple-areolar complex resection required for preoperative imaging or pathologically confirmed nipple involvement;

    Inclusion criterion 9

  3. TNM stage T1-2;

    Inclusion criterion 3

    Nodal stage N0-1;

    Inclusion criterion 4

  4. Positive baseline pregnancy test

    Exclusion criterion 18

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06938360, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female patients aged 18-70 years with primary breast cancer;
  • Histopathologically confirmed invasive breast cancer (meeting latest ASCO/CAP guidelines criteria) with:
  • TNM stage T1-2;
  • Nodal stage N0-1;
  • Ductal carcinoma in situ (DCIS) with maximum tumor diameter <3 cm;
  • Paget's disease;
  • Neoadjuvant chemotherapy permitted for eligible patients;
  • Unicentric lesion confirmed by breast ultrasound, mammography, and MRI;
  • Nipple-areolar complex resection required for preoperative imaging or pathologically confirmed nipple involvement;
  • Enrolled patients randomized 1:1 to breast-conserving surgery or total mastectomy group;
  • Participants voluntarily signed informed consent forms and completed ethics review procedures.

Exclusion Criteria:

  • Tumor-related characteristics
  • Metastatic or bilateral breast cancer
  • Inflammatory breast cancer
  • Multicentric lesions
  • Comorbidities/treatment history
  • History of other malignancies (except cured cervical carcinoma in situ/basal cell carcinoma/squamous cell carcinoma) or prior anticancer therapy (systemic/local)
  • Major non-breast surgery within 4 weeks before enrollment (excluding diagnostic biopsy/PICC placement) without full recovery
  • Active infections/immune disorders:

HIV/AIDS Viral hepatitis (HBV-DNA≥500 IU/ml; HCV antibody-positive with detectable HCV-RNA) Autoimmune hepatitis HBV/HCV coinfection

  • Allogeneic bone marrow/solid organ transplantation history or planned
  • Cardiovascular diseases:
  • Heart failure or LVEF<50%
  • Uncontrolled arrhythmias (resting heart rate>100 bpm, ventricular tachycardia, Mobitz II/third-degree AV block)
  • Angina requiring antianginal drugs
  • Clinically significant valvulopathy
  • Transmural myocardial infarction on ECG
  • Uncontrolled hypertension (SBP>180 mmHg and/or DBP>100 mmHg)
  • Reproductive status

Pregnancy/lactation, or reproductive-aged women with:

  • Positive baseline pregnancy test
  • Refusal of effective contraception
  • Neuropsychiatric disorders Epilepsy, dementia, psychoactive substance abuse, or alcoholism
  • Other investigator-determined exclusionary conditions

Quoted from ClinicalTrials.gov, NCT06938360, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06938360, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06938360